Panitumumab: a review of clinical pharmacokinetic and pharmacology properties after over a decade of experience in patients with solid tumors
J Kast, S Dutta, VV Upreti - Advances in Therapy, 2021 - Springer
Panitumumab is a fully human monoclonal antibody that binds to the epidermal growth
factor receptor (EGFR), thereby inhibiting the growth and survival of tumors expressing …
factor receptor (EGFR), thereby inhibiting the growth and survival of tumors expressing …
Is bodyweight-based dosing truly better than flat dosing for panitumumab?[Response to letter]
MZ Liao, J Kast, M Berkhout, H Prenen… - Clinical …, 2020 - Taylor & Francis
Thank you for the opportunity to respond to the letter by Dr. Hendrikx and colleagues. We
wish to thank Dr. Hendrikx and colleagues for their interest in our recent publication by Liao …
wish to thank Dr. Hendrikx and colleagues for their interest in our recent publication by Liao …
Is bodyweight-based dosing truly better than flat dosing for panitumumab?
JJMA Hendrikx, JH Beijnen… - Clinical Pharmacology …, 2020 - Taylor & Francis
With great interest we read the paper by Liao et al in which they compared a 2-weekly
bodyweight-based (6 mg/kg) and fixed (480 mg) administration of panitumumab, a …
bodyweight-based (6 mg/kg) and fixed (480 mg) administration of panitumumab, a …